Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | PAK4 | O96013 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 1/20 | 0.58 |
| ▸ | MET | P08581 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | PRKACA | P17612 | 1/20 | 0.58 |
| ▸ | FLT1 | P17948 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746365 | 0.74 | NOX4 (0.63) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL6643900 | 0.74 | CHEK1 (1.00) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL11411739 | 0.71 | GAA (1.00) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL4746103 | 0.71 | NOX4 (1.00) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL3265613 | 0.70 | CHEK1 (0.67) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL14446897 | 0.70 | SLC11A2 (0.52) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL1232067 | 0.70 | TSHR (0.48) | GSK3AGSK3BGAAKDM2BKDM4C | |
| Phosphine SCHEMBL9466938 | 0.68 | TSHR (0.47) | GSK3AGSK3BGAAKDM2BKDM4C | |
| SCHEMBL14041252 | 0.68 | SLC11A2 (0.94) | GAAMAPK1KDM2BKDM4CSLC11A2 | |
| SCHEMBL10545898 | 0.68 | VHL (0.77) | GAAMAPK1NOX4NOX1VHL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057687-A | Method for preparing pyridyl pyrazolidinone carboxylic acid compounds | 沈阳中化农药化工研发有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-114057687-A | Method for preparing pyridyl pyrazolidinone carboxylic acid compounds | 沈阳中化农药化工研发有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-9359329-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2016-06-07 | — | — | US | disclosed |
| CN-102333769-B | Derivatives of 2-pyridin-2-yl-pyrazol-3 (2H) -one, preparation thereof, and therapeutic use as HIF activators | SANOFI AVENTIS | 2014-08-27 | — | — | CN | disclosed |
| US-8697731-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2014-04-15 | — | — | US | disclosed |
| US-8541455-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| CN-102333776-A | Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof | SANOFI AVENTIS | 2012-01-25 | — | — | CN | disclosed |
| CN-102333769-A | Derivatives of 2-pyridin-2-yl-pyrazol-3 (2H) -one, preparation thereof, and therapeutic use as HIF activators | SANOFI AVENTIS | 2012-01-25 | — | — | CN | disclosed |
| US-20020156285-A1 | Novel herbicides | KUNZ WALTER (CH) | 2002-10-24 | — | — | US | disclosed |
| US-6369002-B1 | HETERO IS PYRIMIDINE OR PYRIDAZINE; 1-(3-FLUORO-5-CHLORO PYRIDIN-2-YL)-3-METHYL-4-TRIFLUOROMETHYLPYRIMIDIN-2,6-DIONE | SYNGENTA CROP PROPERTIES, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1076656-A2 | N-HETEROARYL-SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | Novartis AG (CH) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055693-A2 | N-HETEROARYL-SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
| WO-1999052893-A1 | N-PYRIDONYL HERBICIDES | NOVARTIS AG (CH) | 1999-10-21 | — | — | WO | disclosed |
| US-5194435-A | Hypoglycemic Agent | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-03-16 | — | — | US | disclosed |
| US-5183825-A | Antidiabetic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-02-02 | — | — | US | disclosed |
| US-4954494-A | Cardiotonic and inotropic agents | RORER PHARMACEUTICAL CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| US-4954494-A | Cardiotonic and inotropic agents | RORER PHARMACEUTICAL CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| WO-1989008108-A1 | PYRIDYL-PYRIDAZINONE AND PYRIDYL-PYRAZOLINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONGESTIVE HEART FAILURE | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-09-08 | — | — | WO | disclosed |
| US-4826835-A | INOTROPIC AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| US-4783463-A | Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure | RORER PHARMACEUTICAL CORPORATION (US) | 1988-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156285-A1 | Novel herbicides | DDT, CBR1, CBR3 | CHEK1 1343/4885AURKA 3971/4885DAPK3 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.